FIGURE 3 from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma In Vivo Models Confers a Major Survival Advantage in a CD24-dependent Manner
Time course of the In vivo modeling of the Zika viral treatment of neuroblastoma tumors. ZIKV was introduced once at a concentration of 2 × 106 pfu for all tumors in NCr nude mice. A, Time course assessment of the application of ZIKV to IMR-32 tumors. Tumor size was measured at day 0, 2, 5, and 7 posttreatment compared with vehicle control treatment. Each timepoint within the study utilized an n = 3 for both vehicle- and Zika-treated cohorts. Error bars represent SD. *, P < 0.05 from Vehicle, unpaired t test, days 2, 5, and 7. B, Viral copy number was also measured in vehicle control treated mice for each timepoint in the IMR-32 tumor model, measuring the tumor, kidneys, spleen, liver, heart, and brain by absolute quantification PCR. C, Time course assessment of the application of ZIKV to SK-N-AS tumors. Tumor size was measured at day 0, 4, 7, and 10 posttreatment compared with vehicle control treatment. Each timepoint within the study utilized an n = 3 for both vehicle- and Zika-treated cohorts. Error bars represent SD. *, P < 0.05 from vehicle, unpaired t test, days 4, 7, and 10. D, Viral copy number was also measured in vehicle control treated mice for each timepoint in SK-N-AS tumor models, measuring the tumor, kidneys, spleen, liver, heart, and brain by absolute quantification PCR. E, Relative expression for CD24 was assessed using qRT-PCR at each timepoint for IMR-32 tumors. F, Relative expression for CD24 was assessed using qRT-PCR at each timepoint for SK-N-AS tumors. Both qRT-PCR studies compare cells with tumors for each neuroblastoma. Expression was normalized to GAPDH. All qPCR data shown are the composite of triplicate wells acquired from triplicate experiments. Error bars represent SD. *, P < 0.05 from In vitro cells, one-way ANOVA for tumor day 0, 4, 7, and10.